



Figure 2. Hierarchical illustration of the relationship between bactericides and the number of mutations able to restore resistance in the *imp4213* strain. Molecules at the top are probes of high-quality OM barriers.

probes. Similarly, mutations in *yfgL* restored resistance to CBPV and moenomycin A, as well as to toxins lower in the hierarchy in Figure 2. In contrast, many mutations conferred resistance to cholic acid (5), none of which protected the bacterium from probes 1–4. There was a clear correlation between the number of ways to suppress toxicity to a small molecule, and the quality of the barrier provided to that small molecule.

The study also revealed a link between the functions of YfgL and Imp.^[7] The wild-type organism is resistant to both CBPV and moenomycin A. Furthermore, individually, certain mutations in either *yfgL* or *imp* can confer sensitivity to both of these compounds. However, the selection experiments described above demonstrated that, in combination, these same mutations restored the antibiotic-resistant phenotype, provided, it turns out, that cell growth is slow. The genetic link between *yfgL* and *imp* argues strongly for a cooperative role for YfgL and Imp in OM biogenesis, and a (direct or indirect) interaction between the proteins.

So what, then, is the link between YfgL and Imp? Other investigations^[8] have shown that YfgL is a lipoprotein that is directed to the periplasmic face

of the OM. A series of experiments^[8] were conducted that aimed to detect a direct interaction between YfgL and Imp, but no such interaction was found. However, coimmunoprecipitation experiments and genetic evidence suggested that YfgL forms a multiprotein complex with three other proteins (YaeT, YfiO and NlpB) that is implicated in the assembly of OM β -barrel proteins. Tight control of OM composition—in particular the highly asymmetric structure of the membrane—is required for impermeability. We have seen that certain YfgL mutants are able to confer CBPV and moenomycin A resistance to the *imp4213* strain. The authors suggest that the mutation of YfgL does not simply reduce the function of the multiprotein complex, but, rather, affects the homeostatic control of OM composition in a specific way.

The use of forward genetics in combination with small-molecule probes of barrier quality is an exciting alternative to conventional chemical genetic approaches. In particular, the use of toxic molecules with very different physicochemical properties allowed permeability defects in the OM to be probed in a highly specific manner. The field of chemical genetics is not restricted to the study of the actual targets of small-mole-

cule probes. Small molecules need to reach their target to function, and can be used to investigate the mechanisms that control the organisation of biological systems. This highlight has outlined the power of small molecules in the context of biological research and the powerful interplay^[10] that is possible between classical and chemical genetics. These approaches are united in their goals: the detailed dissection of the molecular basis of biological mechanisms.

Keywords: bacteria · chemical genetics · membranes · proteins · small-molecule probes

- [1] S. L. Schreiber, *Chem. Eng. News* **2003**, *81*, 51–61.
- [2] a) D. Bellows, M. Tyers, *Science* **2004**, *306*, 67–68; b) T. U. Mayer, *Trends Cell Biol.* **2003**, *13*, 270–277; c) R. Breinbauer, *Angew. Chem.* **2003**, *115*, 1116–1118; *Angew. Chem. Int. Ed.* **2003**, *42*, 1086–1087; d) B. R. Stockwell, *Nat. Rev. Genet.* **2000**, *1*, 116–124.
- [3] A. C. Bishop, J. A. Ubersax, D. T. Petsch, D. P. Matheos, N. S. Gray, J. Blethrow, E. Shimizu, J. Z. Tsien, P. G. Schultz, M. D. Rose, J. L. Wood, D. O. Morgan, K. M. Shokat, *Nature* **2000**, *407*, 395–401.
- [4] M. Sekiya-Kawasaki, A. C. Groen, M. J. T. V. Cope, M. Kaksonen, H. A. Watson, C. Zhang, K. M. Shokat, B. Wendland, K. L. McDonald, J. M. McCaffery, D. G. Drubin, *J. Cell Biol.* **2003**, *162*, 765–772.
- [5] X. Chen, H. Ye, R. Kuruvilla, N. Ramanan, K. W. Scangos, C. Zhang, N. M. Johnson, P. M. England, K. M. Shokat, D. D. Ginty, *Neuron* **2005**, *46*, 13–21.
- [6] D. W. Provance, Jr., C. R. Gourley, C. M. Silan, L. C. Cameron, K. M. Shokat, J. R. Goldenring, K. Shah, P. G. Gillespie, J. A. Mercer, *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 1868–1873.
- [7] N. Ruiz, B. Falcone, D. Kahne, T. J. Silhavy, *Cell* **2005**, *121*, 307–317.
- [8] T. Wu, J. Malinverni, N. Ruiz, S. Kim, T. J. Silhavy, D. Kahne, *Cell* **2005**, *121*, 235–245.
- [9] a) J. Smit, Y. Kamio, H. Nikaido, *J. Bacteriol.* **1975**, *124*, 942–958; b) Y. Kamio, H. Nikaido, *Biochemistry* **1976**, *15*, 2561–2570.
- [10] K. Shokat, *Cell* **2005**, *121*, 163–166.

Received: June 11, 2005